265 related articles for article (PubMed ID: 20306194)
1. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin.
Wittenburg LA; Bisson L; Rose BJ; Korch C; Thamm DH
Cancer Chemother Pharmacol; 2011 Jan; 67(1):83-92. PubMed ID: 20306194
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
[TBL] [Abstract][Full Text] [Related]
5. Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells.
Saha SK; Yin Y; Kim K; Yang GM; Dayem AA; Choi HY; Cho SG
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28498322
[TBL] [Abstract][Full Text] [Related]
6. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
7. A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro.
Rathore K; Cekanova M
Drug Des Devel Ther; 2015; 9():5323-35. PubMed ID: 26451087
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
[TBL] [Abstract][Full Text] [Related]
9. Non-toxic Efficacy of the Combination of Caffeine and Valproic Acid on Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models.
Igarashi K; Yamamoto N; Hayashi K; Takeuchi A; Kimura H; Miwa S; Hoffman RM; Tsuchiya H
Anticancer Res; 2016 Sep; 36(9):4477-82. PubMed ID: 27630284
[TBL] [Abstract][Full Text] [Related]
10. Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer.
Wittenburg LA; Gustafson DL; Thamm DH
Clin Cancer Res; 2010 Oct; 16(19):4832-42. PubMed ID: 20705615
[TBL] [Abstract][Full Text] [Related]
11. A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma.
Wittenburg LA; Ptitsyn AA; Thamm DH
J Cell Biochem; 2012 Mar; 113(3):773-83. PubMed ID: 21976144
[TBL] [Abstract][Full Text] [Related]
12. Chloroquine and valproic acid combined treatment in vitro has enhanced cytotoxicity in an osteosarcoma cell line.
Wang CK; Yu XD; Li Q; Xie G; Teng Y
Asian Pac J Cancer Prev; 2013; 14(8):4651-4. PubMed ID: 24083719
[TBL] [Abstract][Full Text] [Related]
13. Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo.
Machado MC; Bellodi-Privato M; Kubrusly MS; Molan NA; Tharcisio T; de Oliveira ER; D'Albuquerque LA
J Exp Ther Oncol; 2011; 9(2):85-92. PubMed ID: 21699015
[TBL] [Abstract][Full Text] [Related]
14. [Inhibitory effect of valproic acid on xenografted Kasumi-1 tumor growth in nude mouse and its mechanism].
Liu P; Tian X; Shi GR; Jiang FY; Liu BQ; Zhang ZH; Zhao L; Yan LN; Liang ZQ; Hao CL
Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):458-62. PubMed ID: 22213865
[TBL] [Abstract][Full Text] [Related]
15. Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines.
Igarashi K; Kawaguchi K; Kiyuna T; Murakami T; Miwa S; Nelson SD; Dry SM; Li Y; Singh AS; Kimura H; Hayashi K; Yamamoto N; Tsuchiya H; Eilber FC; Hoffman RM
Anticancer Res; 2017 Aug; 37(8):4081-4084. PubMed ID: 28739691
[TBL] [Abstract][Full Text] [Related]
16. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.
Wang Z; Liu Z; Wu S
Oncotarget; 2017 May; 8(19):31465-31477. PubMed ID: 28415557
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.
Sun L; Qian Q; Sun G; Mackey LV; Fuselier JA; Coy DH; Yu CY
J Drug Target; 2016; 24(2):169-77. PubMed ID: 26211366
[TBL] [Abstract][Full Text] [Related]
19. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
[TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.
Jones J; Juengel E; Mickuckyte A; Hudak L; Wedel S; Jonas D; Blaheta RA
J Cell Mol Med; 2009 Aug; 13(8B):2376-2385. PubMed ID: 18657224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
